Market cap
$492 Mln
Recently Viewed
Clear All$23.01
$0.00 (0.00%)As on 11-Mar-2024 16:00EDT
Market cap
$492 Mln
Revenue (TTM)
$37 Mln
P/E Ratio
--
P/B Ratio
108.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-16 Mln
ROE
-2.8 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-18.7
Debt to Equity
0
Book Value
$--
EPS
$-8.8
Face value
--
Shares outstanding
21,397,200
CFO
$-328.43 Mln
EBITDA
$-241.67 Mln
Net Profit
$-418.05 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
| 102.4 | 2.5 | 157.4 | 248.6 | -51.4 | -29.4 | -- |
|
BSE Sensex*
| -7.9 | 6.3 | -6.4 | -3.5 | 8.5 | 9.9 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
| 56.7 | -90.4 | -54.5 | 12.3 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
23.0 | 492.4 | 37.3 | -30.9 | -102.2 | -1174.5 | -- | 108.4 |
| 15.3 | 769.0 | 0.0 | -92.6 | -- | -42.8 | -- | 3.3 | |
| 329.8 | 12,599.3 | 0.7 | -433.7 | -75,845.7 | -36.4 | -- | 10.0 |
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the... United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC. Read more
President, CEO, Secretary & Director
Ms. Julie M. Eastland M.B.A.
President, CEO, Secretary & Director
Ms. Julie M. Eastland M.B.A.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Harpoon Therapeutics Inc (HARP) is $23.01 (NASDAQ) as of 11-Mar-2024 16:00 EDT. Harpoon Therapeutics Inc (HARP) has given a return of -51.44% in the last 3 years.
Since, TTM earnings of Harpoon Therapeutics Inc (HARP) is negative, P/E ratio is not available.
The P/B ratio of Harpoon Therapeutics Inc (HARP) is 108.42 times as on 22-Mar-2024, a 2427 premium to its peers’ median range of 4.29 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.04
|
0.45
|
|
2021
|
-0.15
|
0.43
|
|
2020
|
-0.90
|
0.78
|
|
2019
|
-0.70
|
0.39
|
|
2018
|
--
|
--
|
The 52-week high and low of Harpoon Therapeutics Inc (HARP) are Rs -- and Rs -- as of 06-May-2026.
Harpoon Therapeutics Inc (HARP) has a market capitalisation of $ 492 Mln as on 22-Mar-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Harpoon Therapeutics Inc (HARP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.